Prevalence of the metabolic syndrome among schizophrenic patients hospitalized in the Canary Islands

Actas Espanolas de Psiquiatria

Volumn 35, Issue 6, 2007, Pages 359-367

  Moreno, T Sánchez Araña ^a   González, R Touriño ^b   Fleta, J L Hernández ^b   Pérez, P León ^b  

^a HOSPITAL DE LA MERCED   (Spain)

^b UNIVERSITY OF LAS PALMAS DE GRAN CANARIA   (Spain)

Author keywords

Coronary risk; Metabolic syndrome; Prevalence; Schizophrenia

Indexed keywords

ADULT; ARTICLE; FEMALE; HOSPITALIZATION; HUMAN; MALE; METABOLIC SYNDROME X; RESIDENTIAL CARE; SCHIZOPHRENIA; SMOKING; SPAIN; STATISTICS;

ADULT; CATCHMENT AREA (HEALTH); FEMALE; HOSPITALIZATION; HUMANS; MALE; METABOLIC SYNDROME X; SCHIZOPHRENIA; SMOKING; SPAIN;

EID: 37249047516     PISSN: 11399287     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (70)

1. Brown S. Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry 1997;171:502-8.
2. Curkendall SM, Mo J, Glasser DB, Rose Stang M, Jones JK. Cardiovascular disease in patients with schizophrenia in Saskatchewan, Canada. J Clin Psychiatry 2004;65:715-20.
3. Enger C, Weatherby MS, Reynolds RF, Glasser DB, Walker AM. Serious cardiovascular events and mortality among patients with schizophrenia. J Nerv Ment Dis 2004;192:19-27.
4. Newman SC, Bland RC. Mortality in a cohort of patients with schizophrenia: a record linkage study. Can J Psychiatry 1991; 36:224-39.
5. Harris EC, Barraclough B. Excess of mortality of mental disorders. BrJ Psychiatry 1998;177:11-53.
6. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
7. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO consultation, 1999.
8. Balkau B, Charles MA, Drivsholm T, Borch-Johnsen K, Wareham N, Yudkin JS, et al. European Group For The Study Of Insulin Resistance (EGIR). Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes Metab 2002;28:364-76.
9. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004;44:720-32.
10. International Diabetes Federation: The IDF consensus worldwide definition of the metabolic syndrome. Consulted on September 20,2005 in: www.idf.org/webdata/docs/Metabolic_syndrome_definition.pdf.
11. Ford ES. The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey Il Mortality Study. Atherosclerosis 2004;173:309-14.
12. Citrome L Metabolic syndrome and cardiovascular disease. J Psychopharmacol 2005;19(Suppl. 6):84-93.
13. Lorenzo C, Serrano-Rios M, Martínez-Larrad MT, Gabriel R, Williams K, Gómez-Gerique et al. Central adiposity determines prevalence differences of the metabolic syndrome. Obes Res 2003;11:1480-7.
14. Hernández Díaz JF. Prevalencia y características del síndrome metabólico en las islas Canarias. Doctorate thesis. Universidad de la Laguna. Departamento de Medicina y Salud pública, 2005.
15. Saari KM, Lindeman SM, Viilo KM, Isohanni MK, Jarvelin MR, Lauren LH et al. A 4-fold risk of metabolic syndrome in patients with schizophrenia: the Northern Finland 1966 Birth Cohort study. J Clin Psychiatry 2005;66:559-63.
16. McCreadie RG. Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study Br J Psychiatry 2003;183: 534-39.
17. Connolly M, Kelly C. Lifestyle and physical health in schizophrenia. Advan Psychiatr Treat 2005;11:125-32.
18. Thakore JH, Metabolic syndrome and schizophrenia. Br J Psychiatry 2005;186:455-6.
19. Toalson P, Ahmed S, Hardy T, Kabinoff G. The Metabolic Syndrome in Patients With Severe Mental Illnesses. Prim Care Companion J Clin Psychiatry 2004;6:152-8.
20. Thakore JH. Metabolic disturbance in first-episode schizophrenia. Br J Psychiatry Suppl 2004;47:76-9.
21. Dixon L, Weiden P, Delahanty J, Goldberg R, Postrado L, Lucksted A, et al. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull 2000;26:903-12.
22. Henderson DC, Ettinger ER. Schizophrenia and diabetes. Int Rev Neurobiol 2002;51:481-501.
23. Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 2003;160:284-9.
24. Subramaniam M, Chong SA, Pek E. Diabetes mellitus and impaired glucose tolerance in patients with schizophrenia. Can J Psychiatry 2003;48:345-7.
25. Thakore JH, Mann JN, Vlahos I, Martin A, Reznek R. Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia. Int J Obes Relat Metab Disord 2002;26:137-41.
26. Ryan MC, Flanagan S, Kinsella U, Keeling F, Thakore JH. The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia. Life Sci 2004;74:1999-2008,
27. Zhang ZJ, Yao ZJ, Liu W, Fang Q, Reynolds GP. Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia. Br J Psychiatry 2004;184:58-62.
28. Kato MM, Currier MB, Villaverde O, González-Blanco M. The relation between body fat distribution and cardiovascular risk factors in patients with schizophrenia: a cross-sectional pilot study. Prim Care Companion J Clin Psychiatry 2005;7:115-20.
29. Heiskanen T, Niskanen L, Lyytikainen R, Saarinen PI, Hintikka J. Metabolic syndrome in patients with schizophrenia. J Clin Psychiatry 2003;64:575-9.
30. De Hert M, Van Winkel R, Van Eyck D, Hanssens L, Wampers M, Scheen A, et al. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res 2006;83:87-93.
31. Hagg S, Lindblom Y, Mjorndal T, Adolfsson R. High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia. Int Clin Psychopharmacol 2006;21:93-8.
32. Meyer JM, Nasrallah HA, McEvoy JP, Goff DC, Davis SM, Chakos M, et al. The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophr Res 2005;80:9-18.
33. McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005;80:19-32.
34. Kato MM, Currier MB, Gómez CM, Hall L, González-Blanco M. Prevalence of metabolic syndrome in Hispanic and Non-Hispanic Patients With Schizophrenia. Prim Care Companion J Clin Psychiatry 2004;6:74-7.
35. Newcomer JW, Haupt DW. The metabolic effects of antipsychotic medications. Can J Psychiatry 2006;51:480-91.
36. Sánchez-Araña T, Touriño R, Hernández JL, León P. High prevalence of metabolic syndrome in schizophrenic patients: a review of literature. Psiq Biol 2006:13:127-35.
37. Sociedad Española para el Estudio de la Obesidad (SEEDO). Consenso para la evaluación del sobrepeso y la obesidad y el esta
38. blecimiento de criterios de intervención terapéutica. Med Clin 2000;115:587-97.
39. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth edition. Text revision (DSM-IV-TR). Washington, 2000.
40. First MB, Spitzer RL, Gibbon M, Williams JB. Structured Clinical Interview for DSM-IV Axis I Disorders-Clinician version (SCIDCV), Washington: American Psychiatric Press Inc, 1997.
41. Newcomer JW. Medical risk in patients with bipolar disorder and schizophrenia. J Clin Psychiatry 2006;67(Suppl. 9):25-30.
42. Rodríguez O, Delgado M, Apolinaire JJ. Riesgo cardiovascular en pacientes esquizofrénicos con seguimiento ambulatorio en atención primaria de salud, 2005. Consulted on December 4, 2005. In://psiquiatria.com/ articulos/psicosis/esquizofrenia/21818.
43. Goff DC, Sullivan LM, McEvoy JP, Meyer JM, Nasrallah HA, Daumit GL, et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res 2005b;80:45-53.
44. Meyer J, Loh C, Leckband SG, Boyd JA, Wirshing WC, Pierre JM, et al. Prevalence of the metabolic syndrome in veterans with schizophrenia. J Psychiatr Pract 2006;12:5-10.
45. Basu R, Brar JS, Chengappa KN, John V, Parepally H, Gershon S, et al. The prevalence of the metabolic syndrome in patients with schizoaffective disorder-bipolar subtype. Bipolar Disord 2004;6:314-8.
46. Cohn T, Prud'homme D, Streiner D, Kameh H, Remington G. Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can J Psychiatry 2004;49:753-60.
47. Carr DB, Utzschneider KM, Hull RL, Kodama K, Retzlaff BM, Brunzell JD, et al. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes 2004;53:2087-94.
48. Henderson DC, Ettinger ER. Schizophrenia and diabetes. Int Rev Neurobiol 2002;51:481-501.
49. Bushe C, Holt R. Prevalence of diabetes and impaired glucose tolerance in patients with schizophrenia. Br J Psychiatry Suppl 2004;47:67-71.
50. Serrano M, Ascaso JF, Blázquez E, Cabezas J, Carmena R, Escobar F, et al. Grupo de Trabajo Resistencia a la insulina de la Sociedad Española de Diabetes. Resistencia a la insulina y su implicación en múltiples factores de riesgo asociados a diabetes tipo 2. Med Clin 2002;119:458-63.
51. Martínez MJ, Martinez MT, Serrano M. Síndrome de resistencia a la insulina y síndrome metabólico: similitudes y diferencias. Síndrome metabólico: concepto, fislopatología y epidemiologia. Cardiovasc Risk Factors 2003;12:89-95.
52. Ford ES. The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey Il Mortality Study. Atherosclerosis 2004;173:309-14.
53. Alvarez EE, Ribas L, Serra L. Prevalencia del síndrome metabólico en la población de la Comunidad Canaria. Med Clin 2003;120: 172-4.
54. Servicio del Plan de Salud e Investigación del Servicio Canario de Salud. Encuesta de Salud de Canarias 2004. Consejería de Sanidad y Consumo del Gobierno de Canarias. Santa Cruz de Tenerife, 2004. Consulted on December 9, 2005. In: http://www.gobiernodecanarias.org/sanidad/scs/psc.htm.
55. Llerena A, de la Rubia A, Penas-Lledo EM, Díaz FJ, de León J. Schizophrenia and tobacco smoking in a Spanish psychiatric hospital. Schizophr Res 2003;60:313-7.
56. Ortega JM, Gurpegui M, Díaz FJ, de León J. Tabaco y esquizofrenia. Adicciones 2004;16(Suppl. 2):177-90.
57. De León J, Díaz FJ. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res 2005;76:135-57.
58. Lamberti JS, Olson D, Crilly JF, Olivares T, Williams GC, Tu X, et al. Prevalence of the metabolic syndrome among patients receiving clozapine. Am J Psychiatry 2006;163:1273-6.
59. Masand PS, Mago R. Second-generation Antipsychotics and the Metabolic Syndrome. Curr Psychiatry Rep 2005;7:153-4.
60. Newcomer JW. Clinical considerations in selecting and using atypical antipsychotics. CNS Spectr 2005;10(Suppl. 8):12-20.
61. Wirshing DA. Schizophrenia and obesity: impact of antipsychotic medications. J Clin Psychiatry 2004;65(Suppl. 18):13-26.
62. Haddad P. Weight change with atypical antipsychotics in the treatment of schizophrenia. J Psychopharmacol 2005;19(Suppl. 6): 16-27.
63. Homel P, Casey D, Allison DB. Changes in body mass index for individuals with and without schizophrenia, 1987-1996. Schizophr Res 2002;55:277-84.
64. Meyer JM. Effects of atypical antipsychotics on weight and serum lipid levels. J Clin Psychiatry 2001;62(Suppl. 27):27-34.
65. Casey DE, Haupt DW, Newcomer J, Henderson DC, Sernyak MJ, Davidson M, et al. Antipsychotic-Induced weight gain and metabolic abnormalities: Implications for increased mortality in patients with schizophrenia. J Clin Psychiatry 2004;65(Suppl. 7):4-20.
66. Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res 2004;70:1-17.
67. Henderson DC. Schizophrenia and comorbid metabolic disorders. J Clin Psychiatry. 2005;66(Suppl. 6):11-20.
68. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR, Groop L. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24: 683-9.
69. McNeill AM, Rosamond WD, Girman CJ, Golden SH et al. The metabolic syndrome and 11 year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care 2005;28:385-90.
70. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 2004;65:267-72,